Because of the rising frequency of ocular problems among the senior population, the blepharitis treatment market is predicted to increase significantly. Blepharitis mainly affects adults over the age of 50, according to a survey done by the American Academy of Ophthalmology in 2014. Male ocular patients had 37 percent blepharitis, while female ophthalmic patients have 47 percent. The market is also predicted to rise significantly as the number of medications in development grows. For example, InSite Vision's medication ISV-305 is currently in phase 3 clinical studies. ISV-305 is used to treat people who are experiencing early signs of blepharitis.
Read More:
https://bloggerstrive.blogspot.com/2022/03/blepharitis-treatment-market-analysis.html
Click here for Blepharitis Treatment Market Report:
https://www.coherentmarketinsights.com/market-insight/blepharitis-treatment-market-1761
